JP2015501808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501808A5 JP2015501808A5 JP2014543550A JP2014543550A JP2015501808A5 JP 2015501808 A5 JP2015501808 A5 JP 2015501808A5 JP 2014543550 A JP2014543550 A JP 2014543550A JP 2014543550 A JP2014543550 A JP 2014543550A JP 2015501808 A5 JP2015501808 A5 JP 2015501808A5
- Authority
- JP
- Japan
- Prior art keywords
- solid oral
- oral pharmaceutical
- compound
- formulation
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563229P | 2011-11-23 | 2011-11-23 | |
| US61/563,229 | 2011-11-23 | ||
| PCT/US2012/066185 WO2013078264A1 (en) | 2011-11-23 | 2012-11-21 | Pharmaceutical formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182214A Division JP2018035171A (ja) | 2011-11-23 | 2017-09-22 | 医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501808A JP2015501808A (ja) | 2015-01-19 |
| JP2015501808A5 true JP2015501808A5 (https=) | 2016-01-14 |
| JP6216325B2 JP6216325B2 (ja) | 2017-10-18 |
Family
ID=47501412
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543550A Active JP6216325B2 (ja) | 2011-11-23 | 2012-11-21 | 医薬製剤 |
| JP2017182214A Pending JP2018035171A (ja) | 2011-11-23 | 2017-09-22 | 医薬製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182214A Pending JP2018035171A (ja) | 2011-11-23 | 2017-09-22 | 医薬製剤 |
Country Status (38)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| RU2622015C2 (ru) | 2011-11-11 | 2017-06-08 | Новартис Аг | Способ лечения пролиферативного заболевания |
| SI2782557T1 (sl) | 2011-11-23 | 2019-02-28 | Array Biopharma, Inc., | Farmacevtske formulacije |
| KR102369405B1 (ko) | 2015-06-04 | 2022-03-02 | 화이자 인코포레이티드 | 팔보시클립의 고체 투여 형태 |
| RU2615986C1 (ru) * | 2016-02-25 | 2017-04-12 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения |
| CN105816437B (zh) | 2016-03-29 | 2018-08-03 | 深圳市药欣生物科技有限公司 | 一种帕布昔利布的药物制剂及其制备方法 |
| FI3463345T3 (fi) | 2016-06-03 | 2023-01-31 | Farmaseuttisia yhdistelmiä | |
| CN106000220A (zh) * | 2016-06-30 | 2016-10-12 | 东华大学 | 一种含化学试剂的有机溶剂崩解片的制备方法与应用 |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| AU2021358394A1 (en) | 2020-10-05 | 2023-04-13 | Pierre Fabre Medicament | Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma |
| CN114557977A (zh) * | 2022-02-16 | 2022-05-31 | 北京康立生医药技术开发有限公司 | 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法 |
| TR2022009483A2 (tr) * | 2022-06-08 | 2023-12-21 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Palbosiklib içeren bir farmasötik bileşim. |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
| WO2025262137A1 (en) * | 2024-06-21 | 2025-12-26 | Nanoform Finland Oyj | Formulations comprising crystalline nanosized encorafenib |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5475888A (en) | 1977-11-29 | 1979-06-18 | Jiyasuko Kk | Surgical laser |
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
| CA2231050A1 (en) | 1995-09-07 | 1997-03-13 | Biovail International Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| AU754830C (en) | 1997-05-22 | 2004-02-12 | G.D. Searle Llc | Substituted pyrazoles as p38 kinase inhibitors |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
| ME00275B (me) | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
| US6316435B2 (en) | 1999-02-24 | 2001-11-13 | Supergen, Inc. | Combination therapy for lymphoproliferative diseases |
| EP1239831B1 (en) | 1999-12-23 | 2012-10-31 | Mayne Pharma International Pty Ltd. | Improved pharmaceutical compositions for poorly soluble drugs |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| ATE374753T1 (de) | 2001-12-21 | 2007-10-15 | Vernalis Cambridge Ltd | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
| WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| MXPA06007820A (es) | 2004-01-09 | 2006-09-01 | Novartis Ag | Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inhibidores de igf-ir. |
| RU2401265C2 (ru) | 2004-06-10 | 2010-10-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| US7608635B2 (en) | 2005-08-12 | 2009-10-27 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
| EP1919460A2 (en) | 2005-08-22 | 2008-05-14 | Novartis AG | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
| US20080242667A1 (en) | 2005-08-26 | 2008-10-02 | Smithkline Beecham Corporation | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| WO2007105058A2 (en) | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
| WO2007123892A2 (en) | 2006-04-17 | 2007-11-01 | Arqule Inc. | Raf inhibitors and their uses |
| CN103739595A (zh) | 2006-10-02 | 2014-04-23 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| JP2010505859A (ja) | 2006-10-06 | 2010-02-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤およびそれを使用するための方法 |
| EP2089003A1 (en) | 2006-11-09 | 2009-08-19 | Abbott GmbH & Co. KG | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| US20090022789A1 (en) * | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
| WO2009016460A2 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| UA100865C2 (ru) * | 2007-10-19 | 2013-02-11 | Эбботт Гмбх Унд Ко. Кг | Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины |
| CN101861316B (zh) | 2007-11-14 | 2013-08-21 | 奥梅-杨森制药有限公司 | 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| WO2009100176A2 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| WO2009115572A2 (en) | 2008-03-21 | 2009-09-24 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| PT2324008E (pt) | 2008-07-24 | 2012-06-25 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoles como inibidores da proteína quinase |
| CN102123987A (zh) | 2008-07-28 | 2011-07-13 | 吉里德科学公司 | 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物 |
| US8778929B2 (en) | 2008-09-29 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Substituted heteroaryl inhibitors of B-RAF |
| CA2737400C (en) * | 2008-10-07 | 2016-11-22 | Astrazeneca Uk Limited | Pharmaceutical formulation 514 |
| WO2010056662A1 (en) | 2008-11-11 | 2010-05-20 | University Of Washington | Activated wnt-beta-catenin signaling in melanoma |
| ES2422263T3 (es) | 2008-12-19 | 2013-09-10 | Nerviano Medical Sciences Srl | Pirazoles bicíclicos como inhibidores de la proteinquinasa |
| AR075180A1 (es) * | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
| WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| US8546413B2 (en) | 2009-06-15 | 2013-10-01 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| AR077975A1 (es) * | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| CN104958294A (zh) | 2010-01-27 | 2015-10-07 | 内尔维安诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物 |
| CN102918034B (zh) | 2010-03-30 | 2015-06-03 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| EP2601185B1 (en) | 2010-08-03 | 2015-10-07 | Nerviano Medical Sciences S.r.l. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| CA2829263C (en) | 2011-03-21 | 2020-05-12 | Valcuria Ab | A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof. |
| PH12013502523A1 (en) | 2011-06-14 | 2019-10-11 | Novartis Ag | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
| SI2782557T1 (sl) | 2011-11-23 | 2019-02-28 | Array Biopharma, Inc., | Farmacevtske formulacije |
| JP2015536964A (ja) | 2012-11-08 | 2015-12-24 | ノバルティス アーゲー | Ｂ−ｒａｆ阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用 |
-
2012
- 2012-11-21 SI SI201231455T patent/SI2782557T1/sl unknown
- 2012-11-21 EP EP18188984.1A patent/EP3449911B8/en active Active
- 2012-11-21 HU HUE12809882A patent/HUE040370T2/hu unknown
- 2012-11-21 RS RS20181376A patent/RS58048B1/sr unknown
- 2012-11-21 PT PT12809882T patent/PT2782557T/pt unknown
- 2012-11-21 MX MX2014006278A patent/MX353446B/es active IP Right Grant
- 2012-11-21 EA EA201491007A patent/EA025389B1/ru unknown
- 2012-11-21 SG SG11201401260QA patent/SG11201401260QA/en unknown
- 2012-11-21 PL PL12809882T patent/PL2782557T3/pl unknown
- 2012-11-21 JP JP2014543550A patent/JP6216325B2/ja active Active
- 2012-11-21 SM SM20180595T patent/SMT201800595T1/it unknown
- 2012-11-21 US US14/359,121 patent/US9387208B2/en active Active
- 2012-11-21 CA CA2856406A patent/CA2856406C/en active Active
- 2012-11-21 PE PE2014000678A patent/PE20141994A1/es active IP Right Grant
- 2012-11-21 AR ARP120104373A patent/AR088936A1/es not_active Application Discontinuation
- 2012-11-21 MY MYPI2014000970A patent/MY172729A/en unknown
- 2012-11-21 ES ES18188984T patent/ES3037966T3/es active Active
- 2012-11-21 LT LTEP12809882.9T patent/LT2782557T/lt unknown
- 2012-11-21 BR BR112014011981A patent/BR112014011981B8/pt active IP Right Grant
- 2012-11-21 CN CN201280056985.9A patent/CN103945831A/zh active Pending
- 2012-11-21 EP EP12809882.9A patent/EP2782557B1/en active Active
- 2012-11-21 DK DK12809882.9T patent/DK2782557T3/en active
- 2012-11-21 HR HRP20181896TT patent/HRP20181896T1/hr unknown
- 2012-11-21 KR KR1020147013457A patent/KR102091295B1/ko active Active
- 2012-11-21 CN CN201610104236.9A patent/CN105708819B/zh active Active
- 2012-11-21 AU AU2012340759A patent/AU2012340759C1/en active Active
- 2012-11-21 ES ES12809882T patent/ES2695099T3/es active Active
- 2012-11-21 WO PCT/US2012/066185 patent/WO2013078264A1/en not_active Ceased
- 2012-11-21 UA UAA201403227A patent/UA115039C2/uk unknown
- 2012-11-22 TW TW101143808A patent/TWI649098B/zh active
- 2012-11-22 JO JOP/2012/0353A patent/JO3493B1/ar active
-
2014
- 2014-04-02 ZA ZA2014/02418A patent/ZA201402418B/en unknown
- 2014-04-08 TN TNP2014000145A patent/TN2014000145A1/en unknown
- 2014-04-28 CO CO14090466A patent/CO6940426A2/es unknown
- 2014-04-28 IL IL232305A patent/IL232305B/en active IP Right Grant
- 2014-05-15 MA MA37033A patent/MA35716B1/fr unknown
- 2014-05-22 CL CL2014001337A patent/CL2014001337A1/es unknown
- 2014-05-22 PH PH12014501157A patent/PH12014501157A1/en unknown
- 2014-05-23 GT GT201400100A patent/GT201400100A/es unknown
-
2016
- 2016-06-10 US US15/179,190 patent/US9763941B2/en active Active
-
2017
- 2017-03-07 US US15/452,239 patent/US10258622B2/en active Active
- 2017-09-22 JP JP2017182214A patent/JP2018035171A/ja active Pending
-
2018
- 2018-03-14 US US15/921,306 patent/US10561654B2/en active Active
- 2018-11-20 CY CY20181101222T patent/CY1121421T1/el unknown
-
2023
- 2023-05-15 EC ECSENADI202334537A patent/ECSP23034537A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501808A5 (https=) | ||
| JP6216325B2 (ja) | 医薬製剤 | |
| US9907789B2 (en) | Sustained-release preparation | |
| ES2674811T3 (es) | Composiciones estables de fesoterodina | |
| KR101093781B1 (ko) | ｐＨ조절제를 함유하는 목시플록사신 고형 조성물 | |
| EP2839829A1 (en) | Sustained release tablet containing levodropropizine and method for preparing same | |
| JP2021518422A (ja) | レナリドミドを含む医薬組成物 | |
| JP2022140430A (ja) | リバーロキサバン含有錠剤 | |
| HK40005622A (en) | Pharmaceutical formulations | |
| NZ623628B2 (en) | Solid oral pharmaceutical formulations comprising amorphous (S)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropy1-1H-pyrazo1-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (Compound A) | |
| TW201729814A (zh) | 固形製劑 | |
| HK1197024B (en) | Pharmaceutical formulations | |
| NZ713151B2 (en) | Sustained-release formulations of colchicine and methods of using same | |
| NZ713151A (en) | Sustained-release formulations of colchicine and methods of using same |